Monsti Capsule 6 mg (Rivastigmine Tartrate)

Adult dose

Administration: Administer rivastigmine orally twice daily with the morning and evening meals. ○ Adults: 1. Treatment of mild to moderate Alzheimer-type dementia The initial dose is 3 mg of rivastigmine daily. For each patient, increase the dose at intervals of at least 2 weeks to the maximum tolerated dose or the maximum recommended dose of 12 mg daily. Because this medicine showed greater efficacy at doses of 6 mg daily and higher in clinical trials, a target dose range of 6~12mg daily is recommended for most patients. Recommended dose titration Administer 1.5mg of this medicine per dose twice daily for at least 2 weeks; if well tolerated, the dose may be increased to 3mg twice daily. For subsequent dose increases, administer 4.5mg per dose twice daily; if well tolerated, after at least 2 weeks the dose may be increased to 6mg per dose twice daily. If adverse reactions (e.g., nausea, vomiting, abdominal pain, or decreased appetite) or weight loss are observed, one or more doses may be omitted. However, if adverse reactions or weight loss persist, reduce the daily dose to the previous dose that was well tolerated. 2. Treatment of mild to moderate dementia associated with Parkinson's disease In a controlled clinical trial in patients with dementia associated with Parkinson's disease, rivastigmine was administered at 3~12mg daily in 2 doses (1.5~6mg per dose twice daily). The initial dose is 1.5mg of this medicine per dose twice daily. Depending on the patient's tolerability, subsequent doses may be increased sequentially, with a minimum interval of 4 weeks between each dose, to 3mg per dose twice daily, then 4.5mg per dose twice daily, and then 6mg per dose twice daily. If adverse reactions (e.g., nausea, vomiting, abdominal pain, or decreased appetite), weight gain, or extrapyramidal symptoms (e.g., tremor) are observed during treatment, omitting one or several doses may reduce these symptoms. If adverse reactions persist, temporarily reduce the daily dose to the previous well-tolerated dose or consider discontinuing treatment. 3. Maximum recommended dose Administer 6 mg of this medicine per dose orally twice daily. 4. Restarting treatment The incidence and severity of adverse reactions generally increase at higher doses. If treatment has been interrupted for more than 3 days, restart at the lowest daily dose and titrate as described above. ○ Patients with hepatic or renal impairment: 1. Exposure is increased in patients with moderate renal impairment and mild to moderate hepatic impairment, and more adverse reactions may occur. Therefore, take particular care when titrating the dose according to individual tolerability. 2. Do not administer to patients with severe hepatic impairment, as no studies have been conducted in these patients.

Child dose

This medication has not been tested in children, so it is not recommended for use in pediatric patients.

This medicine contains the ingredient Rivastigmine and should not be used in certain patients. For example, patients who are allergic to the ingredients of this medicine or who have severe liver dysfunction should not be administered this medication. Additionally, patients who have experienced allergic contact dermatitis after using this medication should be cautious. Patients with heart disease, peptic ulcers, asthma, chronic obstructive pulmonary disease, urinary retention, seizures, or extrapyramidal disorders should use this medication cautiously and consult with healthcare providers as adverse reactions may occur. Gastrointestinal side effects such as nausea, vomiting, and diarrhea can commonly occur with this medication, and they may be more frequent in female patients. Neurogenic symptoms such as dizziness, headache, drowsiness, and tremors have also been reported. When starting treatment, initiate at a low dose and gradually adjust the dosage, as sudden discontinuation or high-dose administration may cause severe vomiting or esophageal damage. This medication may enhance the effects of other cholinergic drugs, so it is essential to inform the healthcare provider about any medications being taken concurrently. Particular attention should be given to interactions with anesthetics, heart medications, and beta-blockers. The safety of this medication has not been sufficiently proven during pregnancy or breastfeeding, hence it should only be administered cautiously when necessary, and breastfeeding should be discontinued. Safety and efficacy in children have not been established, so it is not recommended for use in pediatric patients. In cases of overdose, symptoms such as nausea, vomiting, bradycardia, and confusion may appear, so immediate medical attention should be sought if suspected, and detoxification may be required. This medication should be stored out of the reach of children, and it should not be transferred to other containers for safety. During treatment, regular monitoring of the patient’s weight and adverse reactions is necessary, and in particular, the exacerbation of movement symptoms in Parkinson's disease patients should be closely observed. Caution is needed when driving or operating machinery as dizziness and drowsiness may occur.

• Nausea
• vomiting
• urinary tract infection
• agitation
• confusion
• nightmares
• anxiety
• insomnia
• depression
• hallucinations

This medication should be stored in a tightly sealed container to prevent air or moisture from entering. It is recommended to maintain a storage temperature between 1 degree and 30 degrees Celsius at room temperature. Proper storage helps preserve the medication's efficacy for a long time.

Appearance

A hard capsule with a brown upper part and a light brown lower part containing white to off-white powder.

Package unit

30 capsules/bottle, 100 capsules/bottle